• Sultan A Almdallaleh, Abdulkareem O Alsuwaida, Abdulhadi M Altalhi, Dina M ALJayar, Elzibair E Massad, Mazaher M Hamid, Parameaswari P Jaganathan, and Fadel H Al-Hababi.
• From the Department of Nephrology (Almdallaleh, Altalhi, Massad, Hamid); from the Department of Medicine (ALJayar); from the Department of Research Support (Jaganathan), Research and Innovation Center, King Saud Medical City, from the Department of Medicine (Alsuwaida), King Saud University, and from the Department of Virology Laboratory (Al-Hababi), Riyadh Regional Laboratory, Riyadh, Kingdom of Saudi Arabia.
• Saudi Med J. 2023 Sep 1; 44 (9): 875881875-881.

ObjectivesTo evaluate the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections among patients receiving in-center hemodialysis (ICHD), the relationship between the IgG antibody levels against the virus and SARS-CoV-2-associated symptoms, hemodialysis adequacy, and the antihypertensives used in order to control blood pressure.MethodsA prospective observational study was carried out at a tertiary care center, King Fahad Kidney Center, Riyadh, Kingdom of Saudi Arabia, between November 2020 and January 2021. A total of 214 ICHD patients with end-stage renal disease (ESRD) were included, and the levels of their anti-SARS-CoV-2 IgG antibodies were assessed after obtaining their informed consent.ResultsOur tests indicated that 15% of the patients in the study's population had detectable SARS-CoV-2 IgG antibodies, with more than half of them (53%) being asymptomatic. We also found that ESRD patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had higher levels of SARS-CoV-2 IgG antibodies than patients not receiving this group of medications.ConclusionMore studies are required to assess whether patients with a SARS-CoV-2 infection that do not have an indication for being prescribed ACEIs/ARBs would benefit from receiving these medications.Copyright: © Saudi Medical Journal.

25 keywords...

hide…